Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1158–1161. doi: 10.1038/sj.bjc.6690184

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

J M M Terwogt 1,2, I A M Mandjes 1, H Sindermann 3, J H Beijnen 1,2, W W ten Bokkel Huinink 1
PMCID: PMC2362219  PMID: 10098751

Abstract

Skin deposits from breast cancer can present serious therapeutic problems, especially when resistant to conventional therapy. Topical application of a cytotoxic drug may represent an attractive new treatment modality devoid of major systemic toxicity. Miltefosine was selected because of its efficacy in breast cancer models. A mixture of alkylated glycerols of various chain lengths and water was used as the pharmaceutical vehicle to dissolve and to further facilitate tissue penetration of miltefosine. In our Institute a phase II study was performed to determine the efficacy and tolerability of topically applied miltefosine in patients with cutaneous metastases from breast cancer. Thirty-three patients in total entered the trial. A 6% miltefosine solution was applied once daily in the first week and twice daily in the following weeks. The planned minimum treatment duration was 8 weeks. We found an overall response rate of 43% for 30 evaluable patients, composed of 23% complete response and 20% partial response. The median response duration was 18 weeks, range 8–68. Toxicity consisted mainly of localized skin reactions, which could be controlled by a paraffin-based skin cream and, where appropriate, by dose modification. No systemic toxicities were observed. We conclude that topical miltefosine is an effective treatment modality in patients with skin metastases from breast cancer. © 1999 Cancer Research Campaign

Keywords: miltefosine, topical administration, skin metastases, breast cancer

Full Text

The Full Text of this article is available as a PDF (340.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando K., Kodama K., Kato A., Tamura G., Arima K. Antitumor activity of glyceryl ethers. Cancer Res. 1972 Jan;32(1):125–129. [PubMed] [Google Scholar]
  2. Berkovic D., Grunwald U., Menzel W., Unger C., Hiddemann W., Fleer E. A. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur J Cancer. 1995 Nov;31A(12):2080–2085. doi: 10.1016/0959-8049(95)00350-9. [DOI] [PubMed] [Google Scholar]
  3. Clive S., Leonard R. C. Miltefosine in recurrent cutaneous breast cancer. Lancet. 1997 Mar 1;349(9052):621–622. doi: 10.1016/S0140-6736(05)61570-X. [DOI] [PubMed] [Google Scholar]
  4. Goppelt-Struebe M., Winter I. Effects of hexadecylphosphocholine on fatty acid metabolism: relation to cytotoxicity. Cancer Chemother Pharmacol. 1995;35(6):519–526. doi: 10.1007/BF00686838. [DOI] [PubMed] [Google Scholar]
  5. Hilgard P., Stekar J., Voegeli R., Engel J., Schumacher W., Eibl H., Unger C., Berger M. R. Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur J Cancer Clin Oncol. 1988 Sep;24(9):1457–1461. doi: 10.1016/0277-5379(88)90336-7. [DOI] [PubMed] [Google Scholar]
  6. Planting A. S., Stoter G., Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer. 1993;29A(4):518–519. doi: 10.1016/s0959-8049(05)80142-x. [DOI] [PubMed] [Google Scholar]
  7. Unger C., Damenz W., Fleer E. A., Kim D. J., Breiser A., Hilgard P., Engel J., Nagel G., Eibl H. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol. 1989;28(2):213–217. doi: 10.3109/02841868909111249. [DOI] [PubMed] [Google Scholar]
  8. Unger C., Eibl H. Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug. Lipids. 1991 Dec;26(12):1412–1417. doi: 10.1007/BF02536578. [DOI] [PubMed] [Google Scholar]
  9. Unger C., Sindermann H., Peukert M., Hilgard P., Engel J., Eibl H. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog Exp Tumor Res. 1992;34:153–159. doi: 10.1159/000420840. [DOI] [PubMed] [Google Scholar]
  10. Verweij J., Gandia D., Planting A. S., Stoter G., Armand J. P. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur J Cancer. 1993;29A(5):778–779. doi: 10.1016/s0959-8049(05)80369-7. [DOI] [PubMed] [Google Scholar]
  11. Verweij J., Krzemieniecki K., Kok T., Poveda A., van Pottelsberghe C., van Glabbeke M., Mouridsen H. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer. 1993;29A(2):208–209. doi: 10.1016/0959-8049(93)90177-h. [DOI] [PubMed] [Google Scholar]
  12. Verweij J., Planting A., van der Burg M., Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol. 1992;118(8):606–608. doi: 10.1007/BF01211805. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES